CD8A and non-small cell lung carcinoma: In a study with 34 lung cancer participants (28 NSCLC and 6 SCLC), Li et al. have recently performed a comprehensive analysis of several immune populations, showing that higher levels of natural killer (NK) cells and a higher CD4+/CD8+ cell ratio predicted longer PFS at ICI treatment baseline.